TRUSOPT OPHTHALMIC SOLUTION 2% [SIN08880P]
Active ingredients: DORZOLAMIDE HCL EQV DORZOLAMIDE
Last updated on 9 October 2026
Product Info
TRUSOPT OPHTHALMIC SOLUTION 2%
[SIN08880P]
Product information
Active Ingredient and Strength | DORZOLAMIDE HCL EQV DORZOLAMIDE - 2% |
Dosage Form | SOLUTION |
Manufacturer and Country | SANTEN PHARMACEUTICAL CO., LTD. NOTO PLANT - JAPAN |
Registration Number | SIN08880P |
Licence Holder | SANTEN PHARMACEUTICAL ASIA PTE. LTD. |
Forensic Classification | PRESCRIPTION ONLY MEDICINES |
Anatomical Therapeutic Chemical (ATC) code | S01EC03 |
Prescription-only Medicines with Exemptions for Supply without Prescription | NA |
Indication
INDICATIONS
TRUSOPT Ophthalmic Solution is indicated in the treatment of elevated intraocular pressure in patients with:
ocular hypertension
open-angle glaucoma
pseudoexfoliative glaucoma and other secondary open-angle glaucomas
Dosing
DOSAGE AND ADMINISTRATION
When used as monotherapy, the dose is one drop of TRUSOPT Ophthalmic Solution in the affected eye(s) three times daily.
When used as adjunctive therapy with an ophthalmic beta-blocker, the dose is one drop of TRUSOPT in the affected eye(s) two times daily.
When substituting TRUSOPT for another ophthalmic antiglaucoma agent, discontinue the other agent after proper dosing on one day, and start TRUSOPT on the next day.
If more than one topical ophthalmic drug is being used, the drugs should be administered at least ten minutes apart.
Contraindications
CONTRAINDICATIONS
TRUSOPT is contraindicated in patients who are hypersensitive to any component of this product.